Shinya Ishiko

Dr. Shinya Ishiko


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
HYHiroshi Yamaguchi
Hiroshi Yamaguchi
KNKandai Nozu
Kandai Nozu
SIShinya Ishiko
Shinya Ishiko
AKAtsushi Kondo
Atsushi Kondo
TNTakeshi Ninchoji
Takeshi Ninchoji
AIAkihito Ishida
Akihito Ishida
The coronavirus disease (COVID-19) pandemic altered environmental factors. We studied the impact of these changes on asthma exacerbation (AE) by comparing the AE-related environmental factors between COVID-19 (2020) and pre-COVID-19 (2011–2019) eras. Between 2011 and 2020, 278,465 children (<16 years old) visited our emergency department, and 7476 were diagnosed with AE. The number of patients showed spring and fall peaks in 2011–2019. Multivariate analyses showed significant positive relationships of the number of AE patients with the average temperature among all patients and 0–5-year-olds and with sulfur dioxide (SO2) levels in 2011–2019 among 0–5-year-olds. Although the spring peak in the number of patients was not observed in 2020 after declaration of a state of emergency, the fall peak was again observed after the state of emergency was lifted. No changes in average temperature were detected, but SO2 was significantly reduced following declaration of the state of emergency in 2020. Therefore, SO2 reduction might have contributed to the disappearance of the peak of AE. However, a fall peak was observed again in 2020, although SO2 levels continued to be low. These data suggest that person to person interaction seems to be associated with AE, presumably due to unknown viral infections.

20 August 2020 in Scientific Reports
Verified
Journal Article
Open access
PDF file
SIShinya Ishiko
Shinya Ishiko
THTomoko Horinouchi
Tomoko Horinouchi
RFRika Fujimaru
Rika Fujimaru
YSYuko Shima
Yuko Shima
HKHiroshi Kaito
Hiroshi Kaito
KNKandai Nozu
Kandai Nozu
Galactose-deficient IgA1 (Gd-IgA1) is important in the pathogenesis of IgA nephropathy (IgAN). A Gd-IgA1-specific monoclonal antibody (KM55) has revealed glomerular Gd-IgA1 deposition solely in patients with IgAN and IgA vasculitis with nephritis (IgAV-N). However, this specificity is controversial and has not been demonstrated in pediatric patients. Here, we conducted double-immunofluorescence staining of IgA and Gd-IgA1 in 60 pediatric patients with various glomerular diseases. We divided patients into four groups: (1) patients with IgAN and IgAV-N (n = 23); (2) patients with immunocomplex-mediated glomerulonephritis accompanied by IgA deposition, including lupus nephritis, membranoproliferative glomerulonephritis, and membranous nephropathy (n = 14); (3) patients with other glomerular diseases involving IgA deposition, including idiopathic nephrotic syndrome (INS), oligomeganephronia, Alport syndrome, dense deposit disease, and crescentic glomerulonephritis (n = 11); and (4) patients with IgA-negative diseases including INS, membranoproliferative glomerulonephritis, membranous nephropathy, oligomeganephronia, Alport syndrome, C3 glomerulonephritis, poststreptococcal acute glomerulonephritis, and hemolytic uremic syndrome (n = 12). KM55 staining revealed Gd-IgA1-positive findings in 23/23 patients in Group 1 and 13/14 patients in Group 2, but not in patients in Groups 3 or 4. Therefore, KM55 may detect incidental IgA deposition in pediatric patients. Gd-IgA1 may be involved in the pathogenesis of these immune-related diseases; alternatively, KM55 may recognize IgA-related immunocomplexes in a non-specific manner.

1 October 2023 in American Journal of Physiology-Heart and Circulatory Physiology
Verified
Journal Article
Closed access
SIShinya Ishiko
Shinya Ishiko
GRGhada Ben Rahoma
Ghada Ben Rahoma
SKSharath Kandhi
Sharath Kandhi
AHAn Huang
An Huang
DSDong Sun
Dong Sun
Vascular endothelial cells represent the first line of exposure to bacterial endotoxins. Here, we propose a novel therapeutic strategy using liposomes to deliver preassembled glycocalyx to vascular endothelial cell surface and consequently restore endothelial glycocalyx (EG). We tested liposomal nanocarriers of preassembled glycocalyx (LNPG) in vivo and ex vivo to establish for the first time their expeditious therapeutic efficacy in improving survival of lipopolysaccharides (LPS)-treated mice, as achieved by the restoration of EG and recovery of endothelial function.

11 January 2022 in Pediatric Nephrology
Verified
Journal Article
Closed access
PDF file
SNSadayuki Nagai
Sadayuki Nagai
THTomoko Horinouchi
Tomoko Horinouchi
TNTakeshi Ninchoji
Takeshi Ninchoji
AKAtsushi Kondo
Atsushi Kondo
YAYuya Aoto
Yuya Aoto
KNKandai Nozu
Kandai Nozu

1 August 2024 in American Journal of Physiology-Heart and Circulatory Physiology
Verified
Journal Article
Closed access
SIShinya Ishiko
Shinya Ishiko
AKAkos Koller
Akos Koller
WDWensheng Deng
Wensheng Deng
AHAn Huang
An Huang
DSDong Sun
Dong Sun
In sepsis, the degradation of the endothelial glycocalyx leads to increased venular permeability. In this study, we developed a potentially new therapeutic approach by in vivo administration of liposomal nanocarriers of preassembled glycocalyx to mice, which restored venular sensitivity to wall shear stress and permeability in lipopolysaccharide-induced sepsis, likely by restoring the integrity of the endothelial glycocalyx. Using a new microchamber system, the permeability of Evans blue dye could be quantitatively determined.

20 March 2021 in Clinical and Experimental Nephrology
Verified
Journal Article
Open access
PDF file
SIShinya Ishiko
Shinya Ishiko
ATAkihito Tanaka
Akihito Tanaka
ATAsami Takeda
Asami Takeda
MHMasayuki Hara
Masayuki Hara
NHNaoto Hamano
Naoto Hamano
KNKandai Nozu
Kandai Nozu
Background Pathological findings in Alport syndrome frequently show mesangial proliferation and sometimes incidental IgA deposition, in addition to unique glomerular basement membrane (GBM) changes including thin basement membrane and/or lamellation. However, similar GBM abnormalities are also often observed in IgA nephropathy. Both diseases are also known to show hematuria, proteinuria, and sometimes macrohematuria when associated with viral infection. Therefore, it can be difficult to make a differential diagnosis, even based on clinical and pathological findings. Some recent articles demonstrated that galactose-deficient IgA1 (Gd-IgA1)-specific monoclonal antibody (KM55) could potentially enable incidental IgA deposition to be distinguished from IgA nephropathy. Methods We performed comprehensive gene screening and glomerular Gd-IgA1 and type IV collagen α5 chain immunostaining for five cases with both IgA deposition and GBM changes to confirm that Gd-IgA1 can help to distinguish these two diseases. Results Four of the cases were genetically diagnosed with Alport syndrome (Cases 1–4) and one was IgA nephropathy with massive GBM changes, which had a negative gene test result (Case 5). In Cases 1–4, glomerular Gd-IgA1 deposition was not detected, although there was positivity for IgA in the mesangial area. In Case 5, glomerular Gd-IgA1 deposition was observed. Conclusion Gd-IgA1 expression analysis could clearly differentiate these two disorders. This approach can be applied to identify these two diseases showing identical clinical and pathological findings.